Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Mobile Hemp Oil Supplement Powder Packet, ChrgD+, Utilizes DehydraTECH Technology

• LXRP partners with Cultivating Wellness Inc. (“CW”) to formulate the ChrgD+ premium brand and will now focus on selling it to CW’s national distribution network of retailers
• The two-gram powder packets are water soluble and can be added to any hot/cold beverage; they are a ready-mix hemp oil supplement that can be added to drinks, such as coffee
• DehydraTECH has already received multiple patents, and LXRP is a drug delivery platform innovator; the introduction is seen as a first step in the relationship between the companies

Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) introduction of ChrgD+ powder packets, which can add multi-spectrum hemp oil to any hot or cold drink, leverages the trademarked ability of the company’s DehydraTECH to deliver cannabinoids. LXRP’s partnership with Cultivating Wellness Inc. (“CW”), which formulated the product, is seen as an important combined effort (http://cnw.fm/qe9AH).

LXRP has not only partnered with CW as the manufacturer of ChrgD+; it also serves as the distributor of the product to its national network of customers, such as convenience stores, specialty retailers, national accounts and grocery chains. It is seen as the beginning of an important partnership between the two companies.

In a news release, Chris Bunka, CEO of LXRP, said, “It’s a simple way to add a multi spectrum powdered hemp supplement to your favorite beverage at any time and enjoy its fast-acting, non-altered taste with no oily residue. Lexaria’s ChrgD+ product format is being evaluated by others for use in their psychoactive cannabinoids products sector as per our proven track record as a technology provider to the industry.”

Based in British Columbia, Canada, LXRP is a biotechnology company and drug delivery platform innovator that has developed DehydraTECH technology, which has shown faster and more effective delivery of cannabinoids and nicotine. LXRP’s IP portfolio already includes a patent for oral delivery of all cannabinoids. The newest patents are to protect LXRP’s cannabinoid-infused beverage compositions. The compositions use both non-psychoactive cannabinoids, such as CBD, and also psychoactive cannabinoids, such as THC.

LXRP has a growing IP portfolio and will license in any of the countries worldwide where its technology already has a patent or is patent-pending. DehydraTECH is its proprietary absorption technology platform. It hopes to be granted two new Australian patents by year’s end. If patents applied for are issued, LXRP will then hold 12 issued patents within its first patent family, “Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof.” It recently received two new U.S. patents related to cannabinoid-infused beverage compositions using DehydraTECH.

For more information, visit the company’s website at www.LexariaBioscience.com

More from PsychedelicNewsWire

• NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Files Abbreviated New Drug Application for Preservative-Free IV Ketamine NRX-100 Amid Ongoing Shortage
• NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic Network
• NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Announces $10.3 Million Financing to Expand HOPE Clinic Network, Advances FDA Drug Approval

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) PsychedelicNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. PNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled visibility, recognition and brand awareness. PNW is where news, content and information converge.

To receive instant SMS alerts, text HEMPWIRE to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/disclaimer/

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com